PADCEV (enfortumab vedotin-ejfv) improved overall survival at planned interim analysis of phase 3 EV-301 trial in previously treated patients with locally advanced or metastatic urothelial cancer

This trial to support regulatory submission in US, in patients previously treated with platinum-based chemotherapy and PD-1/L1 inhibitor, was stopped early due to positive results (30% reduction in risk of death compared to chemotherapy; HR 0.70; 95% CI 0.56, 0.89; p=0.001).

Source:

Biospace Inc.